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Maintenance of cell-wall integrity in Mycobacterium tuberculosis
is essential and is the target of several antitubercular drugs. For
example, ethambutol targets arabinogalactan and lipoarabino-
mannan (LAM) biosynthesis through the inhibition of several arabi-
nofuranosyltransferases. Apart from their role in cell-wall integrity,
mycobacterial LAMs also exhibit important immunomodulatory
activities. Here we report the isolation and detailed structural char-
acterizationof auniqueLAMmoleculederived fromMycobacterium
smegmatis deﬁcient in the arabinofuranosyltransferase AftC (AftC-
LAM). This mutant LAM expresses a severely truncated arabinan
domain completely devoid of 3,5-Araf–branching residues, reveal-
ing an intrinsic involvement of AftC in the biosynthesis of LAM.
Furthermore, we found that ethambutol efﬁciently inhibits biosyn-
thesis of the AftC-LAM arabinan core, unambiguously demonstrat-
ing the involvement of the arabinofuranosyltransferase EmbC in
early stages of LAM-arabinan biosynthesis. Finally,wedemonstrate
that AftC-LAM exhibits an enhanced proinﬂammatory activity,
which is due to its ability to activate Toll-like receptor 2 (TLR2). Over-
all, our efforts furtherdescribe themechanismofactionof an impor-
tant antitubercular drug, ethambutol, and demonstrate a role for
speciﬁc arabinofuranosyltransferases in LAM biosynthesis. In addi-
tion, the availability of sufﬁcient amounts of chemically deﬁned
wild-type and isogenic truncated LAMs paves the way for further
investigations of the structure–function relationship of TLR2 activa-
tion by mycobacterial lipoglycans.
arabinofuranosyltransferase | lipoarabinomannan | Mycobacterium
tuberculosis | cell wall | ethambutol
Tuberculosis (TB) affects a third of humankind and causes 1.7million deaths annually (1). The spread of TB has been fa-
cilitated in recent decades due to the susceptibility of HIV-
infected individuals toMycobacterium tuberculosis, the etiological
agent of TB (2). The problem has been compounded by the
emergence of multi- and extensively drug-resistant M. tuber-
culosis strains (3). M. tuberculosis resides within the family of
Corynebacteriaceae. A common feature of this family is that they
possess an unusual cell-wall architecture dominated by an es-
sential heteropolysaccharide termed arabinogalactan (AG),
which is linked to both mycolic acids and peptidoglycan, forming
the mycolyl–arabinogalactan–peptidoglycan complex (4–6). The
formation of the arabinan domain of AG results from the sub-
sequent addition of arabinofuranose (Araf) residues by a set of
unique arabinofuranosyltransferases (AraTs). The front-line
drug ethambutol (EMB) has been shown to target at least three
AraTs (EmbA, EmbB, and EmbC) (7, 8), but shows no inhibitory
effects against the other recently identiﬁed cell-wall AraTs, such
as AftA (9), AftB (10), and AftC (11). In a previous study, we
successfully deleted MSMEG2785 (Ms-aftC) (11) and showed
that this leads to expression of a severely truncated AG structure
with branching defects in its arabinan domain. Apart from AG,
mycobacteria contain several other glycoconjugates. Lipoara-
binomannan (LAM), which contains an arabinan domain that is
structurally similar to that of AG, is a major component of the
cell wall. It consists of a core mannan domain covalently linked to a
mannosyl–phosphatidyl–myo–inositol (MPI) anchor, which makes
it structurally similar to its biochemical precursor lipomannan
(LM) (12–14). Both LAM and LM exhibit immunomodulatory
functions that may inﬂuence the host immune response (reviewed
in ref. 15). Species-speciﬁc differences in the “capping-motifs” of
the nonreducing termini of the arabinan domain—for which three
variants exist, i.e., AraLAM, PI-LAM, and ManLAM (16–20)—
have been shown to be important for this function.
The arabinan domain of LAM is attached to an as-yet-
unidentiﬁed region of the mannan backbone and is thought to be
synthesized in a similar manner to that of arabinan found in AG
(12–14). To date, only one AraT has been implicated in the
biosynthesis of LAM. This enzyme, EmbC, has also been shown
to be targeted by EMB, but to a lesser extent than the cell-wall
core AraTs, EmbA and EmbB (21, 22). The formation of the
arabinan domain of LAM requires an α(1→3) AraT in a similar
manner to AG, thus resulting in the branched motif of LAM.
Here we investigated the potential role of AftC in LAM bio-
synthesis. By analyzing the structure of LAM from a M. smeg-
matis ΔaftC mutant, we demonstrate that AftC carries dual
functionality and is responsible for introducing 3,5-Araf branches
into LAM in addition to AG. Furthermore, we show, by treating
an M. smegmatis ΔaftC mutant with EMB, that EmbC is involved
in the very early steps of the LAM arabinan core synthesis and
that truncation of this domain modulated the immunological
properties of the molecule.
Results
Effects of aftC Inactivation on LM/LAM Biosynthesis. M. smegmatis
wild type (WT) (Fig. 1, lane 1) and M. smegmatis ΔaftC lipoglycans
(Fig. 1, lanes 2–4) were puriﬁed using conventional methods (20)
resulting in the recovery of a highly puriﬁed lipoglycan with an
intermediate size betweenM. smegmatis LAM and LM, now termed
AftC-LAM (Fig. 1, lane 3). Complementation ofM. smegmatisΔaftC
withMs-aftC restored the lipoglycanproﬁle toWTM.smegmatis (Fig.
1, lane 5). Plasmid-borne Mt-aftC also resulted in complementation
of the mutant (Fig. 1, lane 6). The molecular weight of AftC-LAM
was investigated by negative-ion matrix-assisted laser desorption
ionization time-of-ﬂight mass spectrometry (MS). The mass of WT-
LAM and AftC-LAM exhibited broad unresolved peaks centered at
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m/z 15,000 and 8,000, respectively, indicating a weight decrease of
∼7 kDa for the mutant LAM (Fig. S1 A and B).
Structural Characterization of AftC-LAM. The ratio of Ara to Man in
WT-LAM and AftC-LAM was determined using gas chroma-
tography (GC) of alditol acetate derivatives (11) (Fig. S2 A and
C). WT-LAM had a molar ratio of Ara:Man of 2.7:1, which is
consistent with previously reported data (22), whereas, for AftC-
LAM, the Ara:Man ratio was 0.59:1 (Fig. S2 A and C). Com-
plementation of M. smegmatis ΔaftC with either Ms-aftC or Mt-
aftC restored the Ara:Man ratio to that of the wild-type LAM
(Fig. S2 E and G). In M. smegmatis, LAM consists of approx-
imately 71 Ara, 27 Man, and 1 Ins units (22, 23). The loss of 7
kDa for AftC-LAM equates to 45 Ara residues, suggesting that
AftC-LAM contains one or more short arabinan domains of up
to ∼16 Ara residues. The 1H-NMR spectrum of WT-LAM (Fig.
2A) was much more complex than the anomeric region of AftC-
LAM (Fig. 2B). Indeed, the AftC-LAM 1D 1H spectrum exhibits
three major, well-deﬁned resonances characterized by several
overlapping resonances arising from six different classes of gly-
cosidic residues. On the basis of our data for WT-LAM and
previously published work (19), the 13C resonance at δ101 ppm that
correlated to an anomeric proton at δ5.15 ppm with a 1JH1,C1
coupling constant of ≈170 Hz was assigned as 2,6-Manp. The
resonances at δ105 and δ102.3, correlating to protons at δ5.07
and δ4.90, were assigned as t-Manp and 6-Manp, respectively.
The t-β-Araf residues corresponded to δ103.4 with 1H at δ5.16.
The well-separated spin systems for 2-α-Araf attached to the 3-
position (2-α-Araf→3, δ108.2, δ5.27 ppm) and the 5-position (2-
α-Araf→5, δ108.5, δ5.20) of the 3,5-Araf were also visible in the
spectra of WT-LAM. Several spin systems were observed (δ110.3
and δ5.19 ppm, δ110.3 and δ5.14 ppm, and δ110.3 and δ5.11
ppm) assigned to 5-α-Araf in different chemical environments
with one overlapping set of 3,5-α-Araf (δ110.2-δ5.12) for WT-
LAM. As reported, two distinct chemical shifts of t-α-Araf could
occur for the respective arms of a branched 3,5-α-Araf, as
observed for 2-α-Araf→3 and 2-α-Araf→5 (19). In AftC-LAM
(Fig. 2B), the resonances associated with the mannan core (t-
Manp, 6-Manp, and 2,6-Manp) are conserved, but resonances
associated with Araf residues are notably less abundant. In
particular, 2-α-Araf→3 is absent and the complex set of signals
for the different 5-α-Araf are much more simpliﬁed due to the
loss of 3,5-α-Araf (Fig. 2B). GC/MS of per-O-methylated alditol
acetate derivatives conﬁrmed this result in that it showed an
unaltered glycosidic linkage proﬁle for the mannan backbone of
both WT- and AftC-LAM and a complete loss of 3,5-Araf and a
signiﬁcant reduction in t-Araf, 2-Araf, and 5-Araf-linkages for
the latter LAM (Fig. S2 B and D). Complementation of M.
smegmatis ΔaftC with either Ms-aftC or Mt-aftC restored the
glycosyl linkage proﬁle to that of WT (Fig. S2 F and H), demon-
strating that MSMEG2785 (Ms-aftC) and Rv2673 (Mt-aftC) are
functional orthologs. Overall, the compositional analysis suggests
that, as compared to WT-LAM, AftC-LAM has an unaltered
mannan domain composed of an α(1→6)-Manp backbone sub-
stituted by t-Manp units atO-2 positions, to which is attached one
or more short α(1→5)-linked linear arabinan chains (in total
representing ≈12–15 Araf units) terminating in a single β(1→2)
Ara residue (Fig. S3).
Effect of Ethambutol on AftC-LAM Formation. EMB blocks cell-wall
arabinan biosynthesis by targeting the Emb proteins (7, 8). Al-
though EmbC is known to be involved in LAM arabinan biosyn-
thesis (22), its precise role is as yet inconclusive. We exploited the
phenotype ofM. smegmatis ΔaftC and the structural properties of
AftC-LAM to investigate this role. For this, we treated [14C]-
glucose-labeled cultures of M. smegmatis with subinhibitory con-
centrations of EMB, extracted the lipoglycans, and performed a
radiochemical quantiﬁcation of [14C]-incorporated sugars. SDS–
PAGE analysis of the [14C]-LM/LAM pool of WT M. smegmatis
revealed two broad bands corresponding to LAM and LM
migrating to their expected sizes (Fig. 3A, lane 1) and an Ara:Man
ratio of 1.2:1 (Fig. 3B, lane 1). Subsequent analysis of the [14C]-
LM/LAM lipoglycan pool from M. smegmatis ΔaftC resulted in
labeling of AftC-LAM and LM (Fig. 3A, lane 2) and an Ara:Man
ratio of 0.5:1 (Fig. 3B, lane 2). Addition of EMB at 0.5 μg·ml−1
resulted in a decrease in the size of the AftC-[14C]-LAM, an
accumulation of [14C]-LM (Fig. 3A, lane 3), and a corresponding
change in the Ara:Man ratio of 0.3:1 (Fig. 3B, lane 3). Because
Fig. 1. SDS–PAGE analysis of lipoglycans extracted fromM. smegmatis andM.
smegmatis ΔaftC. Lane 1, lipoglycans extracted from M. smegmatis; lane 2,
lipoglycans extracted from M. smegmatis ΔaftC; lane 3, puriﬁed AftC-LAM
fromM. smegmatis ΔaftC; lane 4, puriﬁed LM fromM. smegmatis ΔaftC; lane 5,
lipoglycans extracted from M. smegmatis ΔaftC pMV261-Ms-aftC; and lane 6,
lipoglycans extracted from M. smegmatis ΔaftC pMV261-Mt-aftC.
Fig. 2. Two-dimensional NMR spectra of WT-LAM and AftC-LAM puriﬁed
from M. smegmatis and M. smegmatis ΔaftC. Structural characterization of
WT-LAM (A) and AftC-LAM (B). 1H, 13C HSQC NMR spectra were acquired in
D2O at 313K. Expanded regions (δ 1H: 5.0–5.30; δ 13C: 101–111) are shown.
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AftC-LAM contains an intact mannan core, the only possible
effect of EMB is the direct inhibition of EmbC activity [addition
of the terminal β(1→2) Araf residues by AftB is insensitive to
EMB (9)], thus showing its involvement in the very early stages of
LAM arabinan biosynthesis and inhibition of an α(1→5) AraT.
Notably, we observed that residual [14C]-Ara labeling always
remained upon EMB treatment (Fig. 3B, lane 3), suggesting that
another AraT possibly adds the ﬁrst Araf residue to LM, akin to
AftA in AG biosynthesis (9).
AftC-LAM Displays Proinﬂammatory Properties. LMs, in contrast to
LAMs, are potent proinﬂammatory lipoglycans (24–27). This
difference has been attributed to the presence of the arabinan
domain in LAM, which masks the “bioactive” mannan core (24,
28). To investigate the consequence of the aftC mutation on the
proinﬂammatory activity of LAM, we compared WT- and AftC-
LAM for release of TNF-α by human THP1 cells. Consistent
with earlier studies (24), truncated AftC-LAM, as compared to
WT-LAM, exhibited an increased proinﬂammatory activity (Fig.
4A). LM is a known agonist for TLR2 (29). Therefore, we
investigated the ability of WT- and AftC-LAM to activate this
receptor. HEK293 cells expressing TLR2 were stimulated with
increasing amounts of LAM after which TLR2-dependent IL-8
production was determined. As shown in Fig. 4B, AftC-LAM
induced a much stronger TLR2 activation than did WT-LAM
(∼10-fold). This result demonstrates that the presence of the
full-length arabinan domain somehow hampered TLR2 activa-
tion. Previously, it has been reported that immune stimulatory
activity of some M. smegmatis LAM preparations may have been
caused by lipopeptide contamination (26). To investigate this
issue, both WT and AftC-LAM were pretreated with H2O2 [a
procedure that inactivates lipopeptides (30, 31)], after which they
were retested for their activity on HEK293 TLR2 cells. As shown
in Fig. 4C, pretreatment with H2O2 substantially reduced the
activity of both WT- and AftC-LAM. However, in contrast to
WT-LAM, which lost all of its activity, a substantial part of the
activity arising from AftC-LAM was sustained for up to 168 h of
treatment (Fig. 4C). This was not due to the inactivation of the
H2O2 itself because addition of fresh H2O2 after 96 h did not
further reduce the activity (Fig. 4C). Therefore, we conclude that
both LAM preparations were probably contaminated with lip-
opeptides to a certain extent. Nevertheless, inactivation of these
molecules with H2O2 clearly demonstrated that AftC-LAM was
able to activate TLR2, whereas WT-LAM became completely
inactive for concentrations up to 100 μg·ml−1 (Fig. 4D).
To determine whether the increased proinﬂammatory activity
of AftC-LAM indeed coincided with a more exposed mannan
domain, the ability ofWT- and AftC-LAM to interact with a human
immunoglobulin G Fc construct harboring the extracellular domain
of the C-type lectin dendritic-cell-speciﬁc ICAM-3-grabbing non-
integrin (DC-SIGN) was investigated. DC-SIGN is highly expressed
on dendritic cells and recognizes high-mannose structures (32, 33)
including LM (34) but not PILAM (35). As shown in Fig. 4E, the
reactivity of DC-SIGN–Fc toward AftC-LAM was stronger as
compared to the reactivity againstWT-LAM,demonstrating that the
mannan core of AftC-LAM was more accessible.
Discussion
The data described in this article unequivocally demonstrate that
AftC is responsible for introducing 3,5-Araf branching in the LAM
arabinan domain of M. smegmatis and proposes a previously
undescribedmodel for LAMbiosynthesis (Fig. 5). Furthermore, we
show that EmbC is involved in the very early stages of LAM ara-
binan biosynthesis and that, with the truncation of the arabinan
domain, LAM gains the ability to activate TLR2. Although the
structure of the arabinan domain of LAM is well understood, less
is known of the enzymes involved in its biosynthesis. One important
reason is that Corynebacterium glutamicum, a preferred model
organism to study mycobacterial AG and LM biosynthesis (9–11),
does not produce a convoluted LAM, as present in mycobacteria.
During our investigation of various putative GT-C glycosyl-
transferases, we deleted msmeg2785 (AftC) from M. smegmatis,
which resulted in a phenotype that displayed a severely truncated
AG (11). In the present study, we revisited this mutant in an
attempt to investigate the potential role of AftC in LAM biosyn-
thesis. Chemical analysis revealed that LAM isolated from the aftC
mutant contained an unaltered mannan core, but with one or more
simple arabinan moieties of ≈12–16 Araf units composed of
α(1→5) linkages terminating in a single β(1→2) fashion. It is rea-
sonable to conclude from our data that AftC is not involved in early
arabinanLAMbiosynthesis because amore pronounced truncation
of LAM would then be expected. AftC has dual functionality in
terms of its involvement in the biosynthesis of both AG and LAM.
Attempts to generate an aftC-deﬁcient strain of M. tuberculosis
proved unsuccessful (36), highlighting the essentiality of aftC in
M. tuberculosis and the species’ intolerance to cell-wall changes.
Hence, AftC represents an excellent drug target.
EmbC has long been implicated in the biosynthesis of myco-
bacterial LAM and has been shown to be a target of the front-line
drug EMB (21, 22). However, speculation around its precise
enzymatic function has remained controversial. By using the unique
phenotype of M. smegmatis ΔaftC, we provide unequivocal evi-
dence that EmbC is an α(1→5) AraT, which is inhibited by EMB
(Fig. 3). We now propose a working model, whereby an as-yet-
unidentiﬁed GT-C AraT primes the mannan backbone with sin-
gular Araf residues in much the same way as AftA primes the
galactan backbone ofAG (9). After this priming, EmbCextends the
arabinan chain in an α(1→5) fashion before AftC branches the
polysaccharide with an α(1→3) Araf residue, and the domain is
further matured by a combination of AraTs, including AftC, AftB,
and perhaps other as-yet-unidentiﬁed enzymes (Fig. 5).
Several mycobacterial cell-wall lipoglycans are proin-
ﬂammatory stimuli of the host immune response. Both LM and
LAM are members of a family of mycobacterial lipoglycans that
all contain a conserved MPI anchor (29). Interestingly, LM, in
addition to being a potent inducer of proinﬂammatory cytokines,
also displays strong anti-inﬂammatory properties and represses
lipopolysaccharide (LPS)-induced cytokine responses in macro-
Fig. 3. SDS–PAGE (A) and total sugar analysis (B) of [14C]-labeled lipoglycans
extracted from M. smegmatis and M. smegmatis ΔaftC treated with EMB.
Growing cultures of M. smegmatis and M. smegmatis ΔaftC were labeled
with [14C]-glucose, and their lipoglycans were extracted and analyzed by
SDS–PAGE (A). Lane 1,M. smegmatis; lane 2,M. smegmatis ΔaftC; and lane 3,
M. smegmatis ΔaftC + 0.5 μg·ml−1 EMB. The above lipoglycans were hydro-
lyzed in 2 M TFA and analyzed by TLC to determine the total sugar com-
position (B). Lane 1, M. smegmatis; lane 2, M. smegmatis ΔaftC; and lane 3,
M. smegmatis ΔaftC + 0.5 μg·ml−1 EMB.
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phages (25). Recently, by making use of LM preparations, sep-
arated by their degree of acylation, it was demonstrated that
these pro- and anti-inﬂammatory properties are, at least in part,
dependent on the degree of acylation (27, 37). Whereas, tri- and
tetra-acylated LM forms displayed strong proinﬂammatory pro-
perties, mono- and di-acylated molecules did not (37). In con-
trast, di-acylated LM was found to be the most potent inhibitor
of LPS-induced cytokine responses, a feature that was indepen-
dent of TLR2, mannose receptor, or SIGNR1 (27). In addition
to the degree of acylation, additional structural features of
MPI-anchored lipoglycans determine their biological activity.
Recently, it was shown that the chain length of the mannan core
Fig. 4. TNF-α production by human THP-1 cells and IL-8 production by HEK293 TLR-2 cells in response to WT-LAM and AftC-LAM. (A) Human THP-1 cells were
incubated with 1 μg·ml−1 (solid bars) or 10 μg·ml−1 (open bars) WT- or AftC-LAM. TNF-αwas quantiﬁed after 24 h by ELISA. (B–D) HEK293 cells transfected with
TLR2 were stimulated with (B) increasing amounts of WT- or AftC-LAM with LPS (50 ng·ml−1), with Pam3CSK4 (50 ng·ml
−1), or with H2O as a negative control;
(C) 50 μg·ml−1 of WT- or AftC-LAM [with and without 1% hydrogen peroxide (±H2O2) for the indicated time period] with LPS (50 ng·ml−1), with Pam3CSK4 (50
ng·ml−1) (±H2O2 for 48 h), or with H2O as a negative control; and (D) with increasing amounts of WT- or AftC-LAM (treated with H2O2 for 168 h). In all cases,
cells were stimulated for 24 h at 37 °C, after which the supernatants were harvested and analyzed for IL-8 by ELISA. (E) Binding of DC-SIGN–Fc to WT- (▴) orAftC-LAM (■) as determined by ELISA. Absorption was measured at 490 nm. In all panels, data are expressed as the mean ± SD from one representative of
three independent experiments.
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of MPI-anchored lipoglycans directly correlated with their ability
to activate TLR2 (26). Whereas lipoglycans with short oligo-
mannopyranosyl backbones, such as the PIMs, were marginally
active, the TLR2-activating potency of lipoglycans with longer
backbones, i.e., LM, was strongly enhanced (26). In addition to
mannan chain length, the type of substitution of the mannan core
was found to be critical, with activity being retained in the case of
Manp substitutions but absent when the core was substituted
with Araf residues (26). This was evidently clear for myco-
bacterial LAMs, which carry a bulky arabinan domain. Although
their LM core would in principle allow for TLR2 activation, the
LAMs were found to be inactive (26). The assumption that the
arabinan domain is directly involved in “silencing activity” is
further sustained by the observation that chemical degradation
of the arabinan domain restores the proinﬂammatory properties
of LAM (24). Our results are in agreement with these ﬁndings as
AftC-LAM, which expresses a severely truncated arabinan do-
main, exhibited an increased proinﬂammatory activity (Fig. 4).
Because WT and AftC-LAM did not differ in their pattern of
acylation or core mannan composition, the increased proin-
ﬂammatory activity must be directly related to the shortening of the
arabinan domain. Exactly how the arabinan domain prevents TLR
activation is currently not fully understood. One thought is that the
arabinan domain exerts its inhibitory effect by steric hindrance (24).
Although several lines of evidence point to this direction, the exact
mechanism and the level at which this occurs remains unclear.
Furthermore, Nigou and coworkers (26) demonstrated that M.
bovis bacillus Calmette–Guérin LAM complexed with soluble
CD14 efﬁciently competes with Pam3CSK4 for binding to TLR2,
suggesting that binding to, and signaling through TLR2, may not be
equal. In several mycobacterial species, the nonreducing termini of
the branched arabinan domain are modiﬁed by capping motifs
consisting of either oligomannosyl, i.e., ManLAMs, or PILAM
units such as inM. smegmatis (16). Whereas reports on the immune
stimulatory properties of ManLAMs are consistent and unambig-
uously demonstrate that these types of LAMs are inactive (24, 26),
some controversy exists on the activity of PILAMs. Early reports
demonstrate that PILAM is proinﬂammatory and signals via TLR2
(17, 24, 38–40). However, the mechanism by which a low degree of
inositol–phosphate capping would confer this proinﬂammatory
activity has never been explained. One hypothesis is that themyo–
inositol–phosphate motif in the MPI-anchored lipoglycans may
mimic the inositol–phosphate caps on PILAMs, thereby conferring
activity. However, the notion that the unsubstituted phospho-
inositol (PI) caps are unlikely to mimic the acylated MPI anchor,
plus the observation that PIMs are only marginally active, clearly
demonstrates that the PI motif alone does not confer activity (24).
Interestingly, in a more recent study, Nigou et al. (26) demon-
strated that highly puriﬁed PILAMs from M. smegmatis and M.
fortuitum were equivalent in activity to ManLAMs. Therefore, in
contrast to what was previously suggested, the authors concluded
that the presence of PI caps did not make LAM proinﬂammatory,
and they suggested that the activity in earlier experiments was
probably due to lipopeptide contamination. Even though con-
taminant lipopeptidesmay not be detected by the current analytical
methods, trace amounts of these molecules (<0.1%) are enough to
inﬂuence the outcomeofmuchmore sensitive biological assays.We
therefore determined the effect of H2O2 treatment on the TLR2-
stimulating activity of both WT and AftC-LAM. As shown in Fig.
4C, treatment with H2O2 severely reduced the activity ofWT-LAM
(PILAM), suggesting that the earlier observed activity was indeed
due to lipopeptide contamination. In contrast, although the activity
of AftC-LAM was also substantially reduced, a stable part of the
activity was insensitive to H2O2 treatment (Fig. 4C). Although we
cannot exclude that H2O2 also acts on LAM and may thereby
abrogate its activity, the observation that the residual activity of
AftC-LAM stabilized after 4 days of treatment, instead of gradually
declining further, argues against this notion. Furthermore, H2O2
treatment fully inactivated the lipopeptide Pam3CSK4, demon-
strating that inactivated lipopeptides do not display any residual
activity (Fig. 4C). Overall, these data strongly suggest that the
proinﬂammatory activity observed in some PILAM preparations
was indeed the result of contaminating lipopeptides. Nevertheless,
on the basis of our experiments, we conclude that truncation of the
arabinan domain by the aftC mutation resulted in an increased
proinﬂammatory activity of AftC-LAM.
Materials and Methods
Bacterial Strains and Growth Conditions. M. smegmatis was grown in tryptic
soy broth (Difco) containing 0.005% Tween 80 (TSBT); solid media included
1.5% agar. Selective media contained 100 μg·mL−1 hygromycin or 20 μg·mL−1
kanamycin. Generation ofM. smegmatis ΔaftCmutants and complementants
was previously reported (11). Minimal inhibitory concentrations were deter-
mined on solid media with various concentrations of EMB and deﬁned as the
lowest EMB concentration inhibiting 100% of growth after 5 days (8). M.
tuberculosis H37Rv DNA was obtained from the National Institutes of Health
Tuberculosis Research Materials and Vaccine Testing Contract at Colorado
State University. All chemicals (unless speciﬁed) were from Sigma-Aldrich.
Extraction and Puriﬁcation of Lipoglycans. Lipoglycans were extracted as
described previously (20, 41). Brieﬂy, dried cells were resuspended in water
and disrupted by sonication; an equal volume of ethanol was added and the
mixture reﬂuxed, followed by centrifugation and recovery of the super-
natant. This extraction process was repeated ﬁve times and the combined
supernatants were dried, subjected to hot-phenol treatment, and dialyzed
against water. The retentate was dried, resuspended in water, and digested
with α-amylase, DNase, RNase, chymotrypsin, and trypsin. The retentate was
dialyzed and subjected to hydrophobic and gel exclusion chromatography
(20, 41). Eluates were collected, dialyzed, concentrated, and analyzed by
SDS–PAGE using Pro-Q emerald glycoprotein stain (Invitrogen).
Glycosyl Composition and Linkage Analysis of WT-LAM and AftC-LAM by NMR
Spectroscopic Analysis and GC/MS. The glycosidic linkage proﬁle of WT-LAM
and AftC-LAM was determined as described (11, 41). Full details of WT-LAM
and AftC-LAM NMR and GC/MS analysis are provided in SI Materials
and Methods.
Treatment of WT-LAM, AftC-LAM, and Pam3CSK4 with H2O2. WT-LAM, AftC-
LAM, and Pam3CSK4 (Invitrogen)were treatedwith H2O2 as described (30, 31).
In short, WT-LAM and AftC-LAM (0.2 mg·mL−1) and Pam3CysK4 (1 μg·mL−1)
were incubated in the dark at 4 °C in the absence or presence of 1% H2O2.
After incubation for various periods of time, the samples were snap-frozen
using liquid nitrogen and lyophilized.
Fig. 5. Mycobacterial LAM biosynthesis and the role of AftC. The GT-A/B
family of glycosyltransferases performs sequential glycosidic transfer of
mannose residues using the high-energy nucleotide GDP-Man to a PI-based
anchor in the cytoplasm. The GT-C family of glycosyltransferases then con-
tinue LM and LAM biosynthesis by elaborating Ac1PIM4 with mannose and
arabinose residues. MptA, MptB, and Rv2181 are the only known ManTs
involved in core mannan biosynthesis, for which they use the lipid-linked
substrate polyprenylphosphomannose (PPM) as the sugar donor. Decaprenyl-
1-monophosphoarabinose (DPA) isusedbyanunknownAraTtoprimeLMatan
as-yet-unidentiﬁedposition. EmbCandAftC are the other two identiﬁedAraTs,
which mature the ﬁnal LAMmolecule before species-speciﬁc capping occurs.
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Cell Culture. THP-1 cells were grown (37 °C, 5%CO2) in RPMI 1640 (Lonza) with
10% FCS (Lonza). HEK293 cells transfected with TLR2 (42) were kept in DMEM
(Invitrogen) containing 10% FCS, 100 units·ml−1 penicillin,100 μg·mL−1 strep-
tomycin, 0.5 mg·mL−1 G418, 2 mM L-glutamine, and 110 mg·L−1 pyruvate.
Cell Stimulation Assays. Cells (HEK293cellswereﬁrst releasedbytrypsinization)
werewashedwithand resuspended in culturemediumat 1.25×106 cells·mL−1.
A total of 80 μL (1 × 105 cells) was transferred to a 96-well U-bottom plate
(Greiner) and left for 2 h, followed by incubations in triplicate with H2O2-
treated WT-LAM, AftC-LAM, and (Pam3CSK4 or with LPS [from Salmonella
enterica serovar Abortusequi (Sigma-Aldrich L5886)] in a ﬁnal stimulation
volume of 100 μL. Unstimulated cells served as controls. Culture supernatants
were harvested after 24 h by centrifugation and stored at −80 °C for cytokine
measurements using ELISA.
Cytokine ELISA. Human IL-8 and TNF-α concentrations were determined in
ELISA according to the manufacturer’s instructions (Invitrogen and R&D
Systems, respectively).
DC-SIGN–Fc ELISA. WT-LAM and AftC-LAM [1 μg·mL−1 in saline (100 μL)] were
coated on NUNCMaxisorp plates overnight at 4 °C. Plates were blockedwith 1%
bovine serum albumin, and serially diluted DC-SIGN–Fc (43) was added for 2 h at
room temperature. Then the plates were washed four times with Tris-buffered
salinewith 1mMMgCl2, 2mMCaCl2, and0.05%Tween-80 (TSMT) and incubated
with goat-anti-human IgG antibody conjugated with peroxidase (Jackson
Immunoresearch). Plates were washed eight times with TSMT and developed
using o-phenylenediamine dihydrochloride and absorptionmeasured at 490 nm.
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